In vitro biopharmaceutic evaluation of capsules containing fluconazole;Avaliação biofarmacêutica in vitro de cápsulas de fluconazol

Revista Brasileira de Ciencias Farmaceuticas/Brazilian Journal of Pharmaceutical Sciences

Volumn 38, Issue 3, 2002, Pages 333-343

  Porta, Valentina ^a   Yamamichi, Érika ^a   Storpirtis, Sílvia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Biopharmaceutical evaluation; Capsules; Dissolution kinetics; Dissolution profile; Fluconazole

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE;

ARTICLE; BRAZIL; CHEMICAL ANALYSIS; DISSOLUTION; DRUG CAPSULE; DRUG SCREENING; DRUG SOLUBILITY; IN VITRO STUDY;

EID: 0036664212     PISSN: 15169332     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Abdou, H. M. Dissolution, Bioavailability and Bioequivalence. Easton: Mack Printing, 1989. p. 7, 73.
2. Amidon, G. L., Lennernäs, H., Shah, V. P., Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., Stuttgart, v.12, n.3, p.413-420, 1995.
3. Aoyagi, N., Ogata, H., Kaniwa, N, Koibuchi, M., Shibazaki, T., Ejima, A. Bioavailability of griseofulvin from tablets in humans and the correlation with its dissolution rate. J. Pharm. Sci., Washington, v.71, n.10, p.1165-1169, 1982.
4. Association Of Official Analytical Chemists. Official Methods of Analysis of AOAC. 16.Ed. Washington, 1995. v.1, pt.1, p.xviii.
5. Atay, O., Selçuk, F. Quantitative determination of fluconazole by infrared spectrophotometry. Anal. Lett., New York, v.29, n. 12, p.2163-2176, 1996.
6. Avico, U., Ciranni, E. S., Zuccaro, P., Cingolani, E., Foschi, F., Paciaroni, E. Caratteristiche biofarmaceutiche delle compresse di digossina. Boll. Chim. Farm., Milano, v.115, n.6, p.432-439, 1976.
7. Bramanti, G. Disponibilitá della fenformina contenuta in una forma farmaceutica orale a cessione protratta. Boll. Chim. Farm., Milano, v.112, p.472-478, 1973.
8. British Pharmacopoeia. London: Her Majesty's Stationery Office, 1999. v.2, p.A211.
9. Dey, M., Enever, R., Marino, M., Michelucci, J., Smith, D., Warner, R., Weierstall, R. Sustained-release etodolac bioavailability and dose proportionality: Correlation between in vivo and in vitro performance. Int. J. Pharm., Amsterdam, v.49, n.2, p.121-128, 1989.
10. Dicionário de especialidades farmacêuticas (DEF 2000/2001). 29. ed. Rio de Janeiro: Publicações Científicas, 2000. 1186p.
11. Dredán, J., Antal, I., Rácz, I. Evaluation of mathematical models describing drug release from lipophilic matrices. Int. J. Pharm., Amsterdam, v. 145, n.1-2, p.61-64, 1996.
12. Drewe, J. Guitard, P. In vitro - In vivo correlation for modified-release formulations. J. Pharm. Sci., Washington, v.82, n.2, p. 132-137, 1993.
13. Eddington, N. D. Development of a level B correlation. In: Workshop Sobre Correlação De Estudos De Biodisponibilidade/Bioequivalência In Vivo E In Vitro (IVIVC). São Paulo, 1999. Apostila. São Paulo: Sindusfarm, 1999. 1v.
14. El-Yazigi, A. Disintegration: Dissolution analysis of percent dissolved - Time data. J. Pharm. Sci., Washington, v.70, n.5, p.535-537, 1981.
15. Führer, C. Crystallographic state and bioavailability. Acta Pharm. Suec., Stockholm, v.15, n.4, p.319, 1978.
16. Ganderton, D. Effect of production variables on the properties of tablets and capsules related to bioavailability. Acta Pharm. Suec., Stockholm, v.15, n.4, p.314-315, 1978.
17. Goracinova, K., Klisarova, L., Simov, A., Fredro-Kumbaradzi, E., Petrusevska-Tozi, L. Preparation, physical characterization, mechanisms of drug/polymer interactions, and stability studies of controlled-release solid dispersion granules containing weak base as active substance. Drug Dev. Ind. Pharm., New York, v.22, n.3, p.255-262, 1996.
18. Grdinic, S., Gjuris, V., Bican-Fister, T. Comparison of in vitro release and renal elimination of 1-butylbiguanide from timed-release oral antidiabetic preparations. Acta Pharm. Jugosl., Zagreb, v.29, n.4, p.215-221, 1979.
19. Hayashi, T., Ogura, T., Takagishi, Y. New evaluation method for in vitro/in vivo correlation of enteric-coated multiple unit dosage forms. Pharm. Res., Stuttgart, v.12, n.9, p.1333-1337, 1995.
20. Langenbucher, F. In vitro tests for bioavailability: Disintegration, diddolution, permeation. Acta Pharm. Suec., Stockholm, v.15, n.4, p.315, 1978.
21. Lin, S. Y., Kao, Y. H., Chang, H. N. Preliminary evaluation of the correlation between in vitro release and in vivo bioavailability of two aminophyline slow-release tablets. J. Pharm. Sci., Washington, v.79, n.4, p.326-330, 1990.
22. Lowenthal, W. Disintegration of tablets. J. Pharm. Sci., Washington, v.61, p.1695-1711, 1972.
23. O'Hara, T., Dunne, A., Kinahan, A., Cunningham, S., Stark, P., Devane, J. Review of methodologies for the comparison of dissolution profile data. Adv. Exp. Med. Biol., New York, v.423, p. 167-171, 1997.
24. Pinho, J. J. R. G., Storpirtis, S. Desenvolvimento e avaliação biofarmacotécnica de comprimidos de liberação controlada de cloridrato de metformina empregando meio de dissolução com variação gradual de pH. Rev. Bras. Ciênc. Farm., São Paulo, v.35, n.1, p.101-109, 1999.
25. Razdan, B., Verma, P. K. Evaluation of dosage forms. III: Studies on commercial acetaminophen tablet dosage forms. Int. J. Pharm., Amsterdam, v.79, n.2-3, p.83-88, 1992.
26. Sjögren, J. Formulation factors influencing the bioequivalence of drug. Acta Pharm. Suec., Stockholm, v. 15, n.4, p.297-298, 1978.
27. Skelly, J. P., Vanbuskirk, G. A., Savello, D. R., Amidon, G. L., Arbit, H.M., Dighe, S., Fawzi, M. B., Gonzalez, M.A., Malick, A. W., Malinowski, H., Nedich, R., Peck, G. E., Pearce, D.M., Shah, V., Shangraw, R. F., Schwartz, J. B., Truelove, J. Scaleup of immediate release oral solid dosage forms. Pharm. Res., Stuttgart, v.10, n.2, p.313-316, 1993.
28. Steinijans, V. W., Dietrich, R., Trautmann, H., Sauter, R., Benedikt, G. A novel approach to the specification of in-vitro dissolution boundaries based on regulatory requirements for bioequivalence. Arzneim.-Forsch./Drug Res., Aulendorf, v.38-II, n.8, p.1238-1240, 1988.
29. United States Pharmacopoeia. 24.Ed. Rockville: United States Pharmacopeial Convention, 2000. p.2000-2002, 2051-2052.
30. Williams, R. L., Upton, R.A., Ball, L., Braun, R.L., Lin, E. T., Liang-Gee, W., Leeson, L. J. Development of a new controlled release formulation of chlorpheniramine maleate using in vitro in vivo correlations. J. Pharm. Sci., Washington, v.80, n.1, p.22-25, 1991.
31. Yau, M. K. T., Meyer, M. C. In vivo - in vitro correlation with a commercial dissolution simulator. II: papaverine, phenytoin and sulfisoxazole. J. Pharm. Sci., Washington, v.72, n.6, p.681-686, 1983.